85 results
Page 4 of 5
F-1
h1r e76c67dijav
1 Apr 21
Registration statement (foreign)
5:29pm
POS AM
rt3pt0vm4c6r1u4ki
22 Mar 21
Prospectus update (post-effective amendment)
4:15pm
D
9wxpqs1d9py8frjd
19 Mar 21
$6M in equity / options / securities to be acquired, sold $6M, 3 investors
4:15pm
6-K
EX-99.1
qc8tos31rrc4
18 Mar 21
PainReform Provides Year-End Business Update and Reports Progress Towards
10:36am
20-F
w2qyh3n
18 Mar 21
Annual report (foreign)
9:03am
6-K
EX-99.1
sosru
9 Mar 21
PainReform Announces $6.0 Million Private Placement
4:15pm
6-K
EX-99.1
ioqacqzk
6 Jan 21
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
9:00am
6-K
EX-99.1
5ku4we
5 Jan 21
Investor Presentation January 2021
4:15pm
6-K
EX-99.1
iypi9
4 Jan 21
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
4:16pm
424B3
jd0 a7tgs
25 Nov 20
Prospectus supplement
11:12am
6-K
EX-99.1
eet8u6zs7i9q1i71wg
25 Nov 20
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
10:08am
6-K
EX-99.1
cr8s3d
13 Nov 20
Report of Foreign Private Issuer
6:09am
6-K
EX-99.1
zo4sm12c1x
9 Nov 20
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
10:30am
6-K
EX-99.1
m48lytd2r5xe e7y
19 Oct 20
PainReform Highlights Surgical Advantages of PRF-110
1:37pm
424B3
6b95zd3bv3jd77zln2
30 Sep 20
Prospectus supplement
4:42pm
6-K
EX-99.2
g3yfs
30 Sep 20
Condensed Financial Statements
4:32pm
424B4
xjjgobe
2 Sep 20
Prospectus supplement with pricing info
4:09pm
F-1/A
4nx4s87lrb brrrd
31 Aug 20
Registration statement (foreign) (amended)
6:06am
F-1/A
26mua t47
24 Aug 20
Registration statement (foreign) (amended)
12:15pm
F-1/A
0tql26 5z8u
10 Aug 20
Registration statement (foreign) (amended)
4:15pm